A guide to selecting high-performing antibodies for amyloid-beta precursor protein for use in Western Blot, immunoprecipitation and immunofluorescence
F1000Research · 2024
DOI: 10.12688/f1000research.139867.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift F1000Research, 2024. Verfasst von Riham Ayoubi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, H…. Hauptthemen laut MEDLINE: Amyloid beta-Protein Precursor, Fluorescent Antibody Technique, Immunoprecipitation, Blotting, Western. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Genome Quebec, Mitacs.
Abstract (Originalsprache)
The amyloid-beta precursor protein is a transmembrane protein expressed in many tissues and highly concentrated in the brain. The protein is of significant interest due to its involvement in the generation of amyloidogenic β-amyloid peptides, prone to plaque formation that is characteristic of Alzheimer’s Disease. The scientific community would benefit from the availability of high-quality anti-amyloid-beta precursor protein antibodies to enhance reproducible research on this target. In this study, we characterized eleven amyloid-beta precursor protein commercial antibodies for Western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a larger, collaborative initiative seeking to address antibody reproducibility issues by characterizing commercially available antibodies for human proteins and publishing the results openly as a resource for the scientific community. While use of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, H3A 2B4, Canada.
ORCID-Profile: Donovan Worrall, Kathleen Southern, Carl Laflamme
Förderung
- NIA NIH HHS
- Genome Quebec
- Mitacs
- Ontario Genomics
- Canadian Institutes of Health Research Foundation
- Genome Canada
- National Institutes of Aging
Zitieren
APA
Ayoubi, R., Fotouhi, M., Worrall, D., Southern, K., Laflamme, C., NeuroSGC/YCharOS/EDDU collaborative group, & ABIF consortium (2024). A guide to selecting high-performing antibodies for amyloid-beta precursor protein for use in Western Blot, immunoprecipitation and immunofluorescence. F1000Research. https://doi.org/10.12688/f1000research.139867.2
Vancouver
Ayoubi R, Fotouhi M, Worrall D, Southern K, Laflamme C, NeuroSGC/YCharOS/EDDU collaborative group, et al. A guide to selecting high-performing antibodies for amyloid-beta precursor protein for use in Western Blot, immunoprecipitation and immunofluorescence. F1000Research. 2024. doi:10.12688/f1000research.139867.2
BibTeX
@article{Ayoubi2024,
author = {Ayoubi, Riham and Fotouhi, Maryam and Worrall, Donovan and Southern, Kathleen and Laflamme, Carl and NeuroSGC/YCharOS/EDDU collaborative group, NeuroSGC/YCharOS/EDDU collaborative group and ABIF consortium, ABIF consortium},
title = {A guide to selecting high-performing antibodies for amyloid-beta precursor protein for use in Western Blot, immunoprecipitation and immunofluorescence},
journal = {F1000Research},
year = {2024},
doi = {10.12688/f1000research.139867.2}
}
EUVIMED